Biomarker Modeling of Alzheimer’s Disease

[1]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[2]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[3]  A. Dale,et al.  Critical ages in the life course of the adult brain: nonlinear subcortical aging , 2013, Neurobiology of Aging.

[4]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[5]  C. Jack,et al.  Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. , 2013, JAMA neurology.

[6]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[7]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[8]  A. Dale,et al.  Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease , 2013, The Journal of Neuroscience.

[9]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[10]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[11]  C. Jack,et al.  Brain injury biomarkers are not dependent on β‐amyloid in normal elderly , 2013, Annals of neurology.

[12]  Miranka Wirth,et al.  Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals , 2013, The Journal of Neuroscience.

[13]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[14]  Gaël Chételat,et al.  Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.

[15]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[16]  William Jagust,et al.  Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration , 2013, Neuron.

[17]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[18]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[19]  W. Jagust,et al.  Apolipoprotein E, Not Fibrillar β-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging , 2012, The Journal of Neuroscience.

[20]  Eric M Reiman,et al.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study , 2012, The Lancet Neurology.

[21]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[22]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[23]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  S. DeKosky,et al.  Amyloid imaging in dementias with atypical presentation , 2012, Alzheimer's & Dementia.

[25]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[26]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[27]  Matthew L Senjem,et al.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. , 2012, Archives of neurology.

[28]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[29]  R. Faragher,et al.  Insights into CNS ageing from animal models of senescence , 2012, Nature Reviews Neuroscience.

[30]  Bradford C. Dickerson,et al.  Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay , 2012, Biological Psychiatry.

[31]  M. Weiner,et al.  A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.

[32]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[33]  Denise C. Park,et al.  &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.

[34]  B. Dickerson,et al.  MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults , 2012, Neurology.

[35]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[36]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[37]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[38]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[39]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[40]  Alan E Hubbard,et al.  Longitudinal change of biomarkers in cognitive decline. , 2011, Archives of neurology.

[41]  Dominic Holland,et al.  Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.

[42]  C. Jack,et al.  Ecology of the aging human brain. , 2011, Archives of neurology.

[43]  A. Fagan,et al.  Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease , 2011, Annals of neurology.

[44]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[45]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[46]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[47]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[48]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[49]  Richard J. Kryscio,et al.  Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies , 2011, Acta Neuropathologica.

[50]  Clifford R. Jack,et al.  Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition , 2011, Alzheimer's & Dementia.

[51]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[52]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[53]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[54]  Kazuhiko Yanai,et al.  18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. , 2011, Brain : a journal of neurology.

[55]  V. Lee,et al.  Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.

[56]  C. Jack,et al.  Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid , 2011, Alzheimer's & Dementia.

[57]  Susan M Resnick,et al.  In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.

[58]  H. Braak,et al.  The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.

[59]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[60]  C. Duyckaerts.  Tau pathology in children and young adults: can you still be unconditionally baptist? , 2011, Acta Neuropathologica.

[61]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[62]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[63]  Sachin Dixit,et al.  APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 , 2010, The Journal of Neuroscience.

[64]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[65]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[66]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[67]  D. Harvey,et al.  Measuring cognitive reserve based on the decomposition of episodic memory variance. , 2010, Brain : a journal of neurology.

[68]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[69]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[70]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[71]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[72]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[73]  Alexander Drzezga,et al.  Amyloid-plaque imaging in early and differential diagnosis of dementia , 2010, Annals of nuclear medicine.

[74]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[75]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[76]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[77]  Wiesje M. van der Flier,et al.  CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.

[78]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[79]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[80]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[81]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[82]  Amity E. Green,et al.  Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, Human brain mapping.

[83]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[84]  Nelleke Tolboom,et al.  Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding , 2009, Journal of Nuclear Medicine.

[85]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[86]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[87]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[88]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[89]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[90]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[91]  N. Filippini,et al.  Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.

[92]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[93]  R. Mahley,et al.  Alzheimer disease: Multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches , 2009, Annals of neurology.

[94]  M. Weiner,et al.  Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease* , 2009, Brain : a journal of neurology.

[95]  G. Frisoni,et al.  Neuroimaging outcomes in clinical trials in Alzheimer’s disease , 2009, The journal of nutrition, health & aging.

[96]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[97]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[98]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[99]  P. Matthews,et al.  Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.

[100]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[101]  B. Miller,et al.  Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.

[102]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[103]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[104]  Norbert Schuff,et al.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls , 2009, NeuroImage.

[105]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[106]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[107]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[108]  M. Mintun,et al.  Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. , 2008, Archives of neurology.

[109]  Michael Weiner,et al.  and the Alzheimer’s Disease Neuroimaging Initiative* , 2007 .

[110]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[111]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[112]  Clifford R. Jack,et al.  Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage , 2008, NeuroImage.

[113]  Norbert Schuff,et al.  3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry , 2008, NeuroImage.

[114]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[115]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[116]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[117]  C. Jack,et al.  β‐amyloid burden is not associated with rates of brain atrophy , 2008, Annals of neurology.

[118]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[119]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[120]  Karen M Rodrigue,et al.  Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. , 2007, Neuropsychology.

[121]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[122]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[123]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[124]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[125]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[126]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[127]  Clifford R. Jack,et al.  Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease , 2005, NeuroImage.

[128]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[129]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[130]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[131]  J. Schneider,et al.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. , 2004, Archives of neurology.

[132]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[133]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[134]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[135]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[136]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[137]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[138]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[139]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[140]  M. Mesulam.  Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.

[141]  K. Davis,et al.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.

[142]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[143]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[144]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[145]  C. Duyckaerts,et al.  Dissociation of Alzheimer type pathology in a disconnected piece of cortex , 1997, Acta Neuropathologica.

[146]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[147]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[148]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[149]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[150]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[151]  A. Roses.  Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[152]  H. Braak,et al.  Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder , 1994, Neurobiology of Aging.

[153]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[154]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[155]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[156]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[157]  D. Pollen,et al.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21. , 1987, Science.

[158]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[159]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[160]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[161]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[162]  L. White.  Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. , 2009, Journal of Alzheimer's disease : JAD.

[163]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[164]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[165]  S. Black.  Neuron to Neuron. , 2000 .

[166]  Neuroplasticity Failure Review in Alzheimer ’ s Disease : Bridging the Gap between Plaques and Tangles , 1999 .